204 related articles for article (PubMed ID: 36931901)
1. Refractory and relapsed hairy-cell leukemia (HCL): casting light on promising experimental drugs in clinical trials.
Robak T; Robak P
Expert Opin Investig Drugs; 2023 Apr; 32(4):311-324. PubMed ID: 36931901
[TBL] [Abstract][Full Text] [Related]
2. Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.
Paillassa J; Safa F; Troussard X
Ther Adv Hematol; 2022; 13():20406207221090886. PubMed ID: 35450208
[TBL] [Abstract][Full Text] [Related]
3. No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
King AC; Kabel CC; Pappacena JJ; Stump SE; Daley RJ
Ann Pharmacother; 2019 Sep; 53(9):922-932. PubMed ID: 30841702
[No Abstract] [Full Text] [Related]
4. Potential breakthroughs with investigational drugs for hairy cell leukemia.
Robak T; Wolska A; Robak P
Expert Opin Investig Drugs; 2015; 24(11):1419-31. PubMed ID: 26329588
[TBL] [Abstract][Full Text] [Related]
5. Moxetumomab pasudotox for the treatment of hairy cell leukemia.
Janus A; Robak T
Expert Opin Biol Ther; 2019 Jun; 19(6):501-508. PubMed ID: 31045462
[No Abstract] [Full Text] [Related]
6. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Falini B; De Carolis L; Tiacci E
Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hairy cell leukemia.
Chihara D; Kreitman RJ
Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
[TBL] [Abstract][Full Text] [Related]
8. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic options for relapsed hairy cell leukemia.
Jain P; Polliack A; Ravandi F
Leuk Lymphoma; 2015; 56(8):2264-72. PubMed ID: 25563425
[TBL] [Abstract][Full Text] [Related]
10. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J; Maitre E; Troussard X
Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
[TBL] [Abstract][Full Text] [Related]
11. Hairy cell leukemia: a brief update on current knowledge and treatment prospects.
Puła A; Robak T
Curr Opin Oncol; 2021 Sep; 33(5):412-419. PubMed ID: 34264896
[TBL] [Abstract][Full Text] [Related]
12. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.
Nobre CF; Newman MJ; DeLisa A; Newman P
Cancer Chemother Pharmacol; 2019 Aug; 84(2):255-263. PubMed ID: 31134324
[TBL] [Abstract][Full Text] [Related]
13. New treatment options in hairy cell leukemia with focus on BRAF inhibitors.
Falini B; Tiacci E
Hematol Oncol; 2019 Jun; 37 Suppl 1():30-37. PubMed ID: 31187521
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues.
Kreitman RJ; Arons E
Blood Rev; 2022 Jan; 51():100888. PubMed ID: 34535326
[TBL] [Abstract][Full Text] [Related]
15. Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Oncologist; 2020 Jan; 25(1):e170-e177. PubMed ID: 31628266
[TBL] [Abstract][Full Text] [Related]
16. Hairy cell leukemia: present and future directions.
Kreitman RJ
Leuk Lymphoma; 2019 Dec; 60(12):2869-2879. PubMed ID: 31068044
[TBL] [Abstract][Full Text] [Related]
17. The pharmacological management of hairy cell leukemia.
Ramos Perez J; Ravandi-Kashani F
Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
[TBL] [Abstract][Full Text] [Related]
18. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
[TBL] [Abstract][Full Text] [Related]
19. Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.
Siddiqui R; Sardar M; Shahzad M; Jose J; Selene I; Shah Z; Qureshi A; Shafqat M; Kashif R; Ahmad M; Mejia-Garcia A; Anwer F
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):659-666. PubMed ID: 34275772
[TBL] [Abstract][Full Text] [Related]
20. Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.
Maitre E; Paillassa J; Troussard X
Front Oncol; 2022; 12():1068981. PubMed ID: 36620555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
